

Special Issue

Selected Papers from Vaccines Summit Boston 2022

Message from the Guest Editor

This Special Issue contains a selection of papers presented at the Vaccines Summit Boston 2022 which will be held on 28–31 March 2022. This Special Issue will highlight the current advances in vaccines, vaccination and immunology. It brings together leading biotech and pharma industry experts, academicians, and decision makers who are passionate about addressing major global issues by turning ideas into solutions. This Special Issue covers the following topics: Novel Live Attenuated Vaccines; Cancer Vaccines; HIV Vaccine; COVID-19 Vaccine R&D; Influenza & Respiratory; Bacterial Vaccines; Emerging & Re-Emerging Diseases; Bioprocessing & Manufacturing; Clinical Trials; Vaccines Safety; Immune Profiling; New Vaccine Development; Vaccine Adjuvants; DNA & RNA Vaccines; Malarial Vaccines; Subunit Vaccines. Selected extended papers from this conference can be submitted to the conference Special Issue with a 25% discount on the article processing charge. We look forward to your submission.

Guest Editor

Dr. William R. Jacobs

Department of Microbiology & Immunology, Albert Einstein College of Medicine, Yeshiva University, New York, NY 10033, USA

Deadline for manuscript submissions

closed (30 August 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/108417

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).